A successful multimodality therapy for a case of recurrent rectal cancer with KRAS mutation

Ayako Watanabe, Ryo Inada, Takeshi Nagasaka, Tomohiko Yagi, Hijiri Matsumoto, Toshiaki Toshima, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Toshiyoshi Fujiwara

Research output: Contribution to journalArticlepeer-review

Abstract

Aman in his 50s underwent high anterior resection for rectosigmoid cancer in January 2010. The primary tumor was diagnosed as a moderately differentiated adenocarcinoma with KRAS mutation, pStage a. In May 2011, the patient had a recurrent lung tumor detected by computed tomography (CT); the tumor was resected using video-assisted thoracoscopic surgery. However, additional recurrent lung tumors arose, and radiofrequency ablation (RFA) was performed to treat these in Febuary 2012. After RFA therapy, capecitabine was administered as adjuvant chemotherapy. Unfortunately, 10 months later, positron emission tomography (PET)/cT suggested a new recurrence in a left lateral lymph node. Although the pelvic lymph node was surgically removed immediately, a new lung recurrence was found on CT three months after the surgery. RFA was again used to treat this lung lesion. After the second RFA, the patient is doing well without any evidence of recurrence. We describe a case of recurrent rectal cancer successfully treated with multimodality therapy. The combination of appropriate locai therapy with systemic chemotherapy is an essential strategy to treat advanced colorectal cancer, especially in patients witl KRAS mutation when anti-EGFR antibodies are not effective.

Original languageEnglish
Pages (from-to)237-239
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number2
Publication statusPublished - Feb 1 2015

Keywords

  • KRAS mutation
  • Multimodality therapy
  • Recurrent colorectal cancers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A successful multimodality therapy for a case of recurrent rectal cancer with KRAS mutation'. Together they form a unique fingerprint.

Cite this